• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼部药物递送中的渗透促进剂

Penetration Enhancers in Ocular Drug Delivery.

作者信息

Moiseev Roman V, Morrison Peter W J, Steele Fraser, Khutoryanskiy Vitaliy V

机构信息

Reading School of Pharmacy, University of Reading, Whiteknights, P.O. Box 224, Reading RG66AD, UK.

MC2 Therapeutics, James House, Emlyn Lane, Leatherhead KT22 7EP, UK.

出版信息

Pharmaceutics. 2019 Jul 9;11(7):321. doi: 10.3390/pharmaceutics11070321.

DOI:10.3390/pharmaceutics11070321
PMID:31324063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6681039/
Abstract

There are more than 100 recognized disorders of the eye. This makes the development of advanced ocular formulations an important topic in pharmaceutical science. One of the ways to improve drug delivery to the eye is the use of penetration enhancers. These are defined as compounds capable of enhancing drug permeability across ocular membranes. This review paper provides an overview of anatomical and physiological features of the eye and discusses some common ophthalmological conditions and permeability of ocular membranes. The review also presents the analysis of literature on the use of penetration-enhancing compounds (cyclodextrins, chelating agents, crown ethers, bile acids and bile salts, cell-penetrating peptides, and other amphiphilic compounds) in ocular drug delivery, describing their properties and modes of action.

摘要

已确认的眼部疾病有100多种。这使得先进眼部制剂的研发成为药学领域的一个重要课题。改善药物眼部递送的方法之一是使用渗透促进剂。这些化合物被定义为能够增强药物跨眼膜渗透性的物质。这篇综述文章概述了眼睛的解剖学和生理学特征,并讨论了一些常见的眼科疾病以及眼膜的渗透性。该综述还分析了有关在眼部药物递送中使用渗透增强化合物(环糊精、螯合剂、冠醚、胆汁酸和胆盐、细胞穿透肽及其他两亲性化合物)的文献,描述了它们的特性和作用方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/87e1471aea01/pharmaceutics-11-00321-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/39bfe8a477b2/pharmaceutics-11-00321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/3a186e491c54/pharmaceutics-11-00321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/b16860b47d12/pharmaceutics-11-00321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/d3c9922d0c05/pharmaceutics-11-00321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/43003c1c745d/pharmaceutics-11-00321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f4b440af8941/pharmaceutics-11-00321-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f99b7c613f9c/pharmaceutics-11-00321-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/b9a03a7523bc/pharmaceutics-11-00321-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/c401becbbffd/pharmaceutics-11-00321-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/a67994b2cf94/pharmaceutics-11-00321-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/7a8cbe1cf892/pharmaceutics-11-00321-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/96de254060d9/pharmaceutics-11-00321-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/4947da76c2f1/pharmaceutics-11-00321-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f31df052bec0/pharmaceutics-11-00321-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f4995fa52ad9/pharmaceutics-11-00321-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/675afdafe621/pharmaceutics-11-00321-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/e72fb727e946/pharmaceutics-11-00321-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/bbc3fba7c83f/pharmaceutics-11-00321-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/87e1471aea01/pharmaceutics-11-00321-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/39bfe8a477b2/pharmaceutics-11-00321-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/3a186e491c54/pharmaceutics-11-00321-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/b16860b47d12/pharmaceutics-11-00321-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/d3c9922d0c05/pharmaceutics-11-00321-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/43003c1c745d/pharmaceutics-11-00321-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f4b440af8941/pharmaceutics-11-00321-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f99b7c613f9c/pharmaceutics-11-00321-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/b9a03a7523bc/pharmaceutics-11-00321-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/c401becbbffd/pharmaceutics-11-00321-g009a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/a67994b2cf94/pharmaceutics-11-00321-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/7a8cbe1cf892/pharmaceutics-11-00321-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/96de254060d9/pharmaceutics-11-00321-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/4947da76c2f1/pharmaceutics-11-00321-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f31df052bec0/pharmaceutics-11-00321-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/f4995fa52ad9/pharmaceutics-11-00321-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/675afdafe621/pharmaceutics-11-00321-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/e72fb727e946/pharmaceutics-11-00321-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/bbc3fba7c83f/pharmaceutics-11-00321-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3868/6681039/87e1471aea01/pharmaceutics-11-00321-g019.jpg

相似文献

1
Penetration Enhancers in Ocular Drug Delivery.眼部药物递送中的渗透促进剂
Pharmaceutics. 2019 Jul 9;11(7):321. doi: 10.3390/pharmaceutics11070321.
2
Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery?冠醚:眼部药物递送的新型通透性增强剂?
Mol Pharm. 2017 Oct 2;14(10):3528-3538. doi: 10.1021/acs.molpharmaceut.7b00556. Epub 2017 Aug 30.
3
Enhancement of ocular drug penetration.眼部药物渗透性的增强。
Crit Rev Ther Drug Carrier Syst. 1999;16(1):85-146.
4
Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery.渗透促进剂与眼部生物黏附剂:眼科药物递送的两条新途径。
Drug Dev Ind Pharm. 2002 Apr;28(4):353-69. doi: 10.1081/ddc-120002997.
5
Understanding the influence of surface properties of nanoparticles and penetration enhancers for improving bioavailability in eye tissues in vivo.了解纳米颗粒和渗透促进剂的表面性质对提高眼组织体内生物利用度的影响。
Int J Pharm. 2016 Mar 30;501(1-2):1-9. doi: 10.1016/j.ijpharm.2016.01.053. Epub 2016 Jan 25.
6
Penetration Enhancers for Topical Drug Delivery to the Ocular Posterior Segment-A Systematic Review.用于眼部后段局部给药的渗透促进剂——一项系统评价
Pharmaceutics. 2021 Feb 18;13(2):276. doi: 10.3390/pharmaceutics13020276.
7
Biomaterials as novel penetration enhancers for transdermal and dermal drug delivery systems.生物材料作为新型经皮和透皮给药系统的渗透增强剂。
Drug Deliv. 2013 Jun-Jul;20(5):199-209. doi: 10.3109/10717544.2013.801533. Epub 2013 Jun 13.
8
Effects of four penetration enhancers on corneal permeability of drugs in vitro.四种渗透促进剂对药物角膜体外通透性的影响。
J Pharm Sci. 1994 Jan;83(1):85-90. doi: 10.1002/jps.2600830120.
9
Discerning the composition of penetratin for safe penetration from cornea to retina.分辨穿透素透过角膜进入视网膜的安全组成。
Acta Biomater. 2017 Nov;63:123-134. doi: 10.1016/j.actbio.2017.09.023. Epub 2017 Sep 18.
10
Recent advances in ocular drug delivery.眼部药物输送的最新进展。
Drug Dev Ind Pharm. 2013 Nov;39(11):1599-617. doi: 10.3109/03639045.2012.736515. Epub 2012 Nov 16.

引用本文的文献

1
Antibacterial Potential of Lucilia sericata (Meigen, 1826) (Diptera: Calliphoridae) Maggot Excretions/Secretions in Presence of Human Tear Fluid.丝光绿蝇(Meigen,1826年)(双翅目:丽蝇科)蛆排泄物/分泌物在人泪液存在下的抗菌潜力
Neotrop Entomol. 2025 Sep 10;54(1):92. doi: 10.1007/s13744-025-01306-1.
2
Cyclodextrin-mediated Enhancement of Haloperidol Solubility: Physicochemical Studies and In Vivo Investigation Using Planaria Worms.环糊精介导提高氟哌啶醇溶解度:物理化学研究及使用涡虫的体内研究
Pharm Res. 2025 Aug;42(8):1373-1383. doi: 10.1007/s11095-025-03909-0. Epub 2025 Aug 15.
3
Targeting Ocular Biofilms with Plant-Derived Antimicrobials in the Era of Antibiotic Resistance.

本文引用的文献

1
A review on recent drug delivery systems for posterior segment of eye.眼部后段的近期药物输送系统综述。
Biomed Pharmacother. 2018 Nov;107:1564-1582. doi: 10.1016/j.biopha.2018.08.138. Epub 2018 Sep 5.
2
New Human Organotypic Corneal Tissue Model for Ophthalmic Drug Delivery Studies.新型人器官型角膜组织模型在眼科药物输送研究中的应用。
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2880-2898. doi: 10.1167/iovs.18-23944.
3
Cell penetrating peptides in ocular drug delivery: State of the art.细胞穿透肽在眼部药物传递中的应用:最新进展。
在抗生素耐药时代,利用植物源抗菌剂靶向眼部生物膜
Molecules. 2025 Jul 5;30(13):2863. doi: 10.3390/molecules30132863.
4
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.眼部局部给药:渗透促进剂的影响
Pharmaceutics. 2025 Mar 31;17(4):447. doi: 10.3390/pharmaceutics17040447.
5
Chitosan-TPP Nanogels for Ocular Delivery of Folic Acid: Release Profile, Corneal Permeation, and Mucoadhesion Assessment.用于眼部递送叶酸的壳聚糖-三聚磷酸钠纳米凝胶:释放曲线、角膜渗透及黏膜粘附性评估
Pharmaceutics. 2025 Mar 27;17(4):424. doi: 10.3390/pharmaceutics17040424.
6
Hybrid NIR-responsive liposome/hydrogel platform mediating chemo-photothermal therapy of retinoblastoma enhanced by quercetin as an adjuvant.混合近红外响应脂质体/水凝胶平台介导视网膜母细胞瘤的化学-光热疗法,槲皮素作为佐剂可增强该疗法。
Theranostics. 2025 Mar 10;15(9):3995-4015. doi: 10.7150/thno.108471. eCollection 2025.
7
Hyaluronic acid conjugates with controlled oleic acid substitution as new nanomaterials for improving ocular co-delivery of cyclosporine A and oleic acid.具有可控油酸取代的透明质酸缀合物作为改善环孢素A和油酸眼部共递送的新型纳米材料。
Asian J Pharm Sci. 2025 Feb;20(1):101009. doi: 10.1016/j.ajps.2024.101009. Epub 2024 Dec 16.
8
Peptide-Bound Aflibercept Eye Drops for Treatment of Neovascular Age-Related Macular Degeneration in Nonhuman Primates.肽结合阿柏西普滴眼液治疗非人灵长类动物的新生血管性年龄相关性黄斑变性
Adv Sci (Weinh). 2025 Mar;12(11):e2410744. doi: 10.1002/advs.202410744. Epub 2025 Jan 30.
9
Development and Characterization of Dual-Loaded Niosomal Ion-Sensitive In Situ Gel for Ocular Delivery.用于眼部给药的双负载脂质体离子敏感原位凝胶的研制与表征
Gels. 2024 Dec 11;10(12):816. doi: 10.3390/gels10120816.
10
Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.青光眼治疗中眼表疾病的管理:一项系统评价。
Bioengineering (Basel). 2024 Oct 11;11(10):1010. doi: 10.3390/bioengineering11101010.
J Control Release. 2018 Aug 28;284:84-102. doi: 10.1016/j.jconrel.2018.06.023. Epub 2018 Jun 18.
4
Freeze-dried matrices for ocular administration of bevacizumab: a comparison between subconjunctival and intravitreal administration in rabbits.用于眼部给予贝伐单抗的冻干基质:兔眼玻璃体内和球结膜下给予的比较。
Drug Deliv Transl Res. 2018 Jun;8(3):461-472. doi: 10.1007/s13346-018-0520-x.
5
Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.基于半氟化烷的系统可增强难溶性药物对角膜的渗透。
Int J Pharm. 2018 Mar 1;538(1-2):119-129. doi: 10.1016/j.ijpharm.2018.01.019. Epub 2018 Jan 12.
6
Use of Animal Models and Techniques in Glaucoma Research: Introduction.青光眼研究中动物模型和技术的应用:引言
Methods Mol Biol. 2018;1695:1-10. doi: 10.1007/978-1-4939-7407-8_1.
7
Crown Ethers: Novel Permeability Enhancers for Ocular Drug Delivery?冠醚:眼部药物递送的新型通透性增强剂?
Mol Pharm. 2017 Oct 2;14(10):3528-3538. doi: 10.1021/acs.molpharmaceut.7b00556. Epub 2017 Aug 30.
8
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.糖尿病视网膜病变:当前的认识、机制及治疗策略
JCI Insight. 2017 Jul 20;2(14). doi: 10.1172/jci.insight.93751.
9
Enhancement and inhibition effects on the corneal permeability of timolol maleate: Polymers, cyclodextrins and chelating agents.对马来酸噻吗洛尔角膜渗透性的增强和抑制作用:聚合物、环糊精和螯合剂。
Int J Pharm. 2017 Aug 30;529(1-2):168-177. doi: 10.1016/j.ijpharm.2017.06.075. Epub 2017 Jun 23.
10
Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.使用细胞穿透肽将抗血管内皮生长因子药物局部递送至眼后段
Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2578-2590. doi: 10.1167/iovs.16-20072.